Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 2 of about 2   

Articles published

NVO 54.97 +0.08 (0.15%)
price chart
Novo Nordisk A/S - Aggressive Growth
On August 9, Novo Nordisk reported second quarter 2012 earnings of $1.60 per American Depository Receipt, up approximately 20% from the year-ago period.
Post-Market News: AIG, UPS, GE, GS, SBUX, BAC, CAT, YHOO, OZM, CMG, KR
Danish drug maker Novo Nordisk A/S (ADR) (NYSE:NVO) (CPH:NOVO-B) said its long-acting insulin Tresiba has been recommended for approval by advisory panel to the European Medicines Agency.